| [1] |
Platoff RM, Kellish AS, Hakim A, et al. Simple versus radical resection for duodenal adenocarcinoma: a propensity score matched analysis of national cancer database[J]. Am Surg, 2021, 87(2): 266-275. DOI: 10.1177/0003134820951432.
doi: 10.1177/0003134820951432
|
| [2] |
边志民. 恶性肠梗阻的治疗[J]. 中国医师杂志, 2020, 22(11): 1601-1605. DOI: 10.3760/cma.j.cn431274-20201026-01446.
doi: 10.3760/cma.j.cn431274-20201026-01446
|
| [3] |
Pedersen K, Foster N, Overman M, et al. O-007-ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA)[J]. Ann Oncol, 2019, 30(Suppl-4): iv128. DOI: 10.1093/annonc/mdz154.006.
doi: 10.1093/annonc/mdz154.006
|
| [4] |
Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical be-nefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8): 773-779. DOI: 10.1200/JCO.2017.76.9901.
doi: 10.1200/JCO.2017.76.9901
|
| [5] |
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1): 1-10. DOI: 10.1200/JCO.19.02105.
doi: 10.1200/JCO.19.02105
pmid: 31682550
|
| [6] |
Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3): 305-314. DOI: 10.1016/S2213-2600(20)30365-9.
doi: 10.1016/S2213-2600(20)30365-9
|
| [7] |
Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.CCR-20-2571.
doi: 10.1158/1078-0432.CCR-20-2571
|
| [8] |
Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. DOI: 10.1001/jama.2021.12836.
doi: 10.1001/jama.2021.12836
|
| [9] |
程传耀, 解智慧, 柴慧芳, 等. mFOLFOX6方案联合卡瑞利珠单抗对微卫星不稳定直肠癌患者免疫功能的影响[J]. 肿瘤基础与临床, 2021, 34(5): 410-413. DOI: 10.3969/j.issn.1673-5412.2021.05.012.
doi: 10.3969/j.issn.1673-5412.2021.05.012
|
| [10] |
Chen J, Quan M, Chen Z, et al. Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial[J]. J Cancer Res Clin Oncol, 2020, 146(10): 2651-2657. DOI: 10.1007/s00432-020-03251-5.
doi: 10.1007/s00432-020-03251-5
|
| [11] |
Waterhouse DM, Garon EB, Chandler J, et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153[J]. J Clin Oncol, 2020, 38(33): 3863-3873. DOI: 10.1200/JCO.20.00131.
doi: 10.1200/JCO.20.00131
|
